Background: Weight gain and associated medical morbidity offset the reduction of extrapyramidal side effects associated with atypical antipsychotics. Efforts to control weight in antipsychotic-treated patients have yielded limited success. Methods: We studied the impact of an intensive 24-week program of diet, exercise, and counseling in 17 chronically psychotic patients (10 women, seven men) who entered at high average body weight (105.0718.4 kg) and body mass index (BMI) (36.674.6 kg/m 2 ). A total of 12 subjects who completed the initial 24 weeks elected to participate in an additional 24-week, less intensive extension phase. Results: By 24 weeks, weight-loss/patient averaged 6.0 kg (5.7%) and BMI decreased to 34.5 (by 5.7%). Blood pressure decreased from 130/83 to 116/74 (11% improvement), pulse fell slightly, and serum cholesterol and triglyceride concentrations changed nonsignificantly. With less intensive management for another 24 weeks, subjects regained minimal weight (0.43 kg). Conclusions: These findings add to the emerging view that weight gain is a major health problem associated with modern antipsychotic drugs and that labor-intensive weight-control efforts in patients requiring antipsychotic treatment yield clinically promising benefits. Improved treatments without weight-gain risk are needed.
Introduction
Long-term treatment with most antipsychotics and many other psychotropic drugs can produce significant weight gain, with the potential for increasing well-known medical risks associated with obesity. [1] [2] [3] [4] [5] [6] [7] Risks of weight gain are particularly high with certain modern antipsychotic agents, notably clozapine and olanzapine, [2] [3] [4] [5] with potent interactions with serotonin (especially 5-HT 2C ) and histamine receptors (especially H 1 and H 3 ) implicated in the neurobiology of obesity. [8] [9] [10] [11] [12] Weight gain associated with long-term psychotropic drug treatment likely adds to risks of metabolic and general medical disorders that may be more prevalent among persons with chronic major mental illnesses independent of treatment. [13] [14] [15] [16] [17] These combined effects probably contribute to several-fold increases of mortality rates associated with endocrine, pulmonary, cardiovascular, and other stress-sensitive medical disorders among psychiatrically ill populations. [18] [19] [20] Among side effects associated with poor adherence to antipsychotic treatment, weight gain is a major factor contributing to the discontinuation of treatment, especially when treatment discontinuation is rapid or abrupt. 21, 22 Weiden et al. 23 likewise observed that obese individuals with schizophrenia were more than twice as likely to be medication-non-adherent than those with normal body mass indexes (BMIs). While treating obesity in the general population has proven to be a challenge, the challenge may be even greater for those who have gained weight largely due to the use of psychotropic medications.
3 It is extremely difficult for chronically and severely mentally ill patients who require antipsychotic treatment to eat less and exercise more when their treatment increases appetite and produces fatigue and sedation, and their illnesses decrease motivation and limit social interactions and activities. Moreover, their typically strained financial resources and social circumstances often limit their access to low-calorie foods and preclude membership in health clubs, access to exercise equipment, and dietary counseling or education. Such general health-promoting activities are rarely provided in contemporary psychiatric clinical services or covered by health insurance programs for psychiatric illness, despite support for their integration into mental health services. 24 Given the severity and high prevalence of weight gain associated with long-term use of psychotropic drugs, and with certain modern antipsychotic agents in particular, it is essential that weight gain be minimized, and emerging obesity reversed. Behavioral intervention programs including both diet and exercise counseling have provided the best evidence for small weight reductions among patients with schizophrenia over short time intervals, 25 however, few such studies have considered the long-term success of these interventions. [26] [27] [28] Accordingly, we now report on preliminary experience for up to 48 weeks with a weight-control program designed to address the special requirements of chronically mentally ill persons who require continued antipsychotic treatment.
Methods
Subjects meeting all of the following criteria were eligible for participation: DSM-IV diagnoses of schizophrenia or schizoaffective disorder, a weight gain of X4.5 kg and an increase in BMI of X5% since starting antipsychotic treatment, and current treatment with an antipsychotic drug alone or in combination with other psychotropic agents. This study aimed to recruit approximately 20 patients, with the expectation that approximately 15 of those would complete the protocol. Recruitment flyers were posted around McLean Hospital grounds to advertise the study, and all consecutive patients who called in to participate were screened and, if eligible, enrolled in the study. All subjects provided written informed consent after review and approval of the study by the McLean Hospital IRB. Following initial medical and psychiatric screening assessments, subjects were interviewed about their eating, activity, exercise, and sleep patterns, and their physical fitness, coordination, balance, and flexibility were assessed. 29 Doses of all medications were held constant throughout the study and anorexic or anticonvulsant agents likely to induce weight loss were excluded. As a program designed for weight reduction among the obese general adult population, TRIADt includes dietary counseling, exercise sessions, and a low-fat, low-calorie food plan. We utilized this approach to evaluate potential weight loss among antipsychotic-treated subjects. Anticipating that study participants may need more dietary education counseling than the general population, we adapted the TRIADt program to meet that need, incorporating additional, more detailed dietary counseling on healthy food choices and portion sizes. This study was divided into two phases, each lasting 24 weeks in duration. In the first phase, all subjects met twice weekly with study staff in groups of eight or nine for diet and exercise counseling. During the initial 4 weeks of the study, a reduced-calorie, nutritionally complete food plan was developed for each subject, which incorporated individual patterns of sleep, activity, and hunger. Women were encouraged to follow a low-fat, 1600 calorie diet, and men were asked to follow a low-fat, 2000 calorie diet.
Sessions lasted 90 min at a weight-management center on hospital grounds that contained a small gymnasium, weightlifting room, kitchen, and meeting rooms. The first 45 min were spent assisting individual participants with problems adhering to their prescribed diets, helping the groups to improve food choices, and developing strategies to decrease overeating. Significant emphasis was placed on meal planning and how to make low-fat choices at restaurants. Lowfat, high-carbohydrate foods (breakfast cereals, rice cakes, fat-free cookies) were recommended as snacks to curb hunger, and subjects were advised to take psychotropic medicines before, rather than after, meals. Some sessions included trips to a food market and opportunities to taste nutritious, easily prepared foods. Four sessions were devoted to identifying strategies to decrease social isolation and inactivity.
Following nutritional counseling, the last 45 min of each meeting was devoted to individualized fitness training. These exercise sessions included cardiovascular workouts on treadmills, rowing machines, stationary cycles, stairclimbing equipment and fast walking on hills on the hospital grounds. Strength-training exercises included use of free weights and resistance bands as well as flexibility and balance drills. Music and dancing were used to maintain enthusiasm for exercise sessions. Rates of perceived exertion and heart rate were closely monitored. Special attention was given to subjects with medication-related impaired balance and coordination. Monthly fitness evaluations allowed subjects to progress to increased levels of exercise and exertion. Subjects were individually advised how to exercise at home for 30 min three times per week and interviewed weekly about adherence to their agreed-upon exercise regimen.
Subjects completing the first phase of the study were given the option to continue the weight management program for a less intensive, 24-week phase 2. Group sessions, as described above, were offered weekly for those choosing to extend participation. Subjects were encouraged to attend as many weekly sessions as possible, with a minimum commitment of one session every 4 weeks, and instructed to follow their diets as individualized in phase 1.
Assessments
The primary efficacy measures, weight and BMI, were recorded weekly, as were pulse and blood pressure. Monthly clinical ratings included the Clinical Global Impressions (CGI; 30 ), and Brief Psychiatric Rating scales (BPRS; 31 ). Adverse effects were also recorded monthly with the 
tended to lose more weight during the initial 24 weeks than those who did not. Losses ranked: mood stabilizer only (6.375.8 kg), moodstabilizer plus antidepressant (6.377.7 kg), antidepressant alone (5.577.5 kg), and neither adjunctive agent (4.473.5 kg), but these differences were nonsignificant (e.g., the maximum difference, t (11 d.f.) ¼ 0.76, P ¼ 0.45). Other factors not significantly associated with weight loss (either in absolute or percentage improvement in weight or BMI) included sex, age, pretrial weight gain or its rate of increase (kg/month); data not shown).
In weeks 24-48, subjects (N ¼ 6) who attended weekly program sessions (half as frequent as in weeks 0-24) lost another 1.573.7 kg, and those who attended less frequently (N ¼ 6) gained 3.271.9 kg. Importantly, final weight (median 102 kg, range 72-114 kg) and BMI (median 36.2, range 27.2-42.3 kg/m 2 ) remained high ( Table 2) . Weight-reduction during antipsychotic treatment F Centorrino et al
Other measures
Other medical measures showed variable decreases by 48 weeks: resting heart rate (by 6%), systolic and diastolic blood pressure (11%), cholesterol (4%), and triglycerides (15%, after an initial increase), and fasting glucose levels were unchanged ( Table 1 ). The QLS revealed no significant differences from baseline to study end point. Clinical ratings of psychiatric status as BPRS (by 2.477.8 points) and CGIseverity scores (by 0.1270.66) improved slightly within the first 6 months and remained stable thereafter, and there were only minimal changes in ratings of neurological or other adverse effects (data not shown). Although instructed to exercise at home between study sessions, most subjects only exercised sporadically throughout the course of the study. The most common reasons reported for poor adherence to the exercise program included the inaccessibility of sidewalks due to poor weather conditions (particularly snow), fatigue, and low motivation. However, all (N ¼ 12) subjects who completed the study managed to halve the time it took for them to complete a quarter-mile uphill walking route on hospital grounds from baseline to study end point.
Discussion
Improving food choices, restricting portion size, and increasing physical activity are basic elements of weight-loss Weight-reduction during antipsychotic treatment F Centorrino et al programs. However, achieving these goals with mentally ill patients poses particular challenges, including difficulty in motivating them to continue in organized programs, limited financial support of all medical services for the chronically and severely mentally ill, and the continuing deleterious physical and metabolic effects of required psychotropic medication. [1] [2] [3] [4] [5] [6] [7] Despite these challenges, our results dispel the belief that chronically ill psychiatric patients are not able, because of mental and physical limitations, to maintain consistent participation in a weight loss program. It is important to note that the present subjects were clinically stable, relatively high functioning (six subjects worked or volunteered, and all but one subject lived alone or with family), and motivated to take part in a weight-loss program. The effectiveness of this program designed specifically to meet the needs of a mentally ill population is highlighted by the fact that with all medication held constant, subjects were able to lose weight (average 6.3 kg and a BMI decrease of 2.0 kg/m 2 ) and decrease blood pressure, pulse rate, and serum cholesterol and triglyceride levels. In their review of weight management programs for patients with schizophrenia, Faulkner et al. 25 found similar reductions in weight with short-term behavioral modification programs in this psychiatric population. Our findings further demonstrate that the weight loss obtained during the initial months of the study were largely sustained for up to 48 weeks during less intensive follow-up. Moreover, the improvements in pulse rate, blood pressure, and serum lipid concentrations, as well as weight and BMI, were also sustained to this end point, even with less frequent intervention. These results parallel those seen in non-psychiatric, obese populations in which 1-year weight losses typically ranged from 1.4 to 5.0 kg. 39, 40 There was also no worsening and even slight improvement in psychiatric symptom ratings, and no new adverse effects. Potential improvements in EPS ratings with fitness training were not realized, probably because baseline scores were low with the use of atypical antipsychotics. The results indicated that subjects were able to participate in a rigorous weight management program without experiencing untoward mental and physical effects. Moreover, subjects benefited socially from their participation in the study, and reported favoring the peer support and encouragement associated with the program. Nevertheless, despite the sustained degree of weight loss, apparent health benefits, and social support system seen in this program, the final median weight (102.1 kg) and BMI (36.2 kg/m 2 ) of the 12 subjects followed for up to 48 weeks remained in the highly overweight range. Additionally, the costly price tag that often accompanies intensive weight loss programs may make such programs an unrealistic option for mentally ill individuals with limited financial resources. The availability of resources from the health care system, however, would help to alleviate the costliness of these programs, making them available to a broader range of individuals and potentially targeting individuals prior to weight gain.
In conclusion, the present findings highlight the importance of ongoing, consistent intervention for those who have found success in a diet and exercise program designed specifically for patients who have gained weight during antipsychotic treatment. Intensive interventions like those employed in this study may be both feasible and effective for some chronically ill, medicated psychiatric patients, but possibly not for many others who are too impaired or impoverished to support access and sustained program participation. Also, the frequency of such interventions may impact their success. In the first 24 weeks of this study, during which subjects met twice weekly with study staff, the rate of weight loss was considerably high; over the succeeding, less intensive 24 weeks, weight was more or less maintained when subjects determined their own frequency of participation. It is unclear whether weight loss would have continued through phase 2 had subjects continued to meet twice weekly. Interestingly, patients receiving concomitant therapy with mood stabilizers lost more weight relative to those not receiving such treatment. Potentially, patients receiving mood-stabilizer cotherapy may have gained more weight prior to baseline than those not receiving such treatment, although this remains unclear.
The success of this program despite the poor adherence to its exercise component suggests that behavioral weight control interventions may potentially be most effective by emphasizing dietary education and calorie restriction. While these results are encouraging, the possible cost/benefit ratios of such programs must be kept in mind, and better means to prevent weight gain with long-term treatment with psychotropic medication must be explored. Selection of drugs with limited weight-gain liability, 1,2 or supplemental therapy with non-stimulant weight-loss promoting agents such as topiramate 41 and zonisamide 42 may be effective options for some patients. Nevertheless, further progress is needed in the development of newer antipsychotics that have greater overall safety and much more limited risk of potential weight gain and other long-term medical complications. 43, 44 
